Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

CERT - Certara, Inc. Последние новости | Finranks

Home

/

CERT

C

Certara, Inc. (CERT)

NMS – Цена в реальном времени. Валюта: USD

5.09

-0.04 (-0.78%)

При закрытии: May 12, 2026, 4:00 PM EDT

5.20

+0.11 (2.16%)

После закрытия: May 12, 2026, 7:42 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript

Certara Q1 Earnings Call Highlights

Certara Q1 Earnings Call Highlights

Certara NASDAQ: CERT reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick.

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara, Inc. (CERT) Q1 Earnings Miss Estimates

Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.

Certara Reports First Quarter 2026 Financial Results

Certara Reports First Quarter 2026 Financial Results

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals.

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Certara Strategic Business Divestiture Comes At Right Time, Says Analyst

Certara Inc. (NASDAQ:CERT) shares are up 2.34% on Wednesday as the company announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business.

Видео

No Data

There is no data to display

Пресс-релизы

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.

Certara Reports First Quarter 2026 Financial Results

Certara Reports First Quarter 2026 Financial Results

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals.

Veristat to Acquire Certara's Regulatory and Medical Writing Business

Veristat to Acquire Certara's Regulatory and Medical Writing Business

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Biotech--Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara's Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The ac.